摘要
目的:评价湖南省人民医院院区2016年利奈唑胺临床应用的合理性及有效安全性,为其临床应用提供参考。方法:采用回顾性研究,利用医院信息管理系统调取2016年使用利奈唑胺患者病例资料,设计调查表,统计用药合理率,分析不合理原因;计算临床治愈率,病原菌清除率及综合治愈率;监测用药前后红细胞、血红蛋白、血小板下降程度。结果:利奈唑胺临床应用合理率为48.1%,不合理原因主要是适应症把握不准确及疗程不合理;临床有效率为40.4%,病原菌清除率为42.3%,综合治愈率为56.4%;骨髓抑制发生率为21.2%,发生的平均年龄为(81.4±8.7)岁,平均用药时间为(13.6±5.6)d。结论:我院区利奈唑胺临床应用合理性有待提高,正确把握适应症和疗程将很大程度提高合理率;综合疗效尚可,老年患者需特别注意骨髓抑制的发生。
AIM： To evaluate the clinical rationality,efficacy and safety of linezolid in our hospital in 2016 and to provide reference for its clinical application. METHODS： A retrospective study was conducted using the medical history data of patients treated with linezolid in 2016. The questionnaire was designed to compile statistics of rational use rate,to analyze the causes of irrational use,and to calculate the clinical cure rate,pathogen clearance rate and comprehensive cure rate,as well as to monitor the red blood cell,hemoglobin and platelet decline after treatment of linezolid. RESULTS： The rational use rate of linezolid was 48. 1%,the irrational reasons are mainly that the indication was unreasonable and the course of treatment was unreasonable.The clinical cure rate was 40. 4%,the pathogen clearance rate was 42. 3%,and the comprehensive cure rate was 56. 4%. The incidence of myelosuppression was 21. 2% in patients whose average age was（ 81. 4 ± 8. 7） years old,and the average course of treatment was（ 13. 6 ± 5. 6） days. CONCLUSION： The rate of clinical rational use of linezolid needs to be improved in our hospital. The correct indication and course of treatment will improve the rational rate to a great extent. And the comprehensive curative effect is acceptable. But special attention should be paid to the occurrence of myelosuppression for the elderly patients.
作者
徐佳
黄琪
杨志玲
XU Jia;HUANG Qi;YANG Zhiling(Hunan Province Peoples Hospital （The First Affiliated Hospital of Hunan Normal University）, the Second De- partment of Pharmacy, Changsha 410016, Hunan, China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2018年第1期110-115,共6页
Chinese Journal of Clinical Pharmacology and Therapeutics
